FdaApplication
BLA 761210
Identifiers
- fda_app_no: BLA761210
Properties
| Property | Value |
|---|---|
| applicant_name | Janssen Biotech, Inc. |
| application_type | BLA |
| approval_date | 2021-05-21 |
Revenue by product
RYBREVANT
| Period | Revenue |
|---|---|
| Q2 2026 | $289.0M |
| Q1 2026 | $257.0M |
| Q4 2025 | $216.0M |
| Q3 2025 | $198.0M |
| Q2 2025 | $179.0M |
| Q1 2025 | $141.0M |
| Q4 2024 | $122.0M |
| Q3 2024 | $89.0M |
| Q2 2024 | $69.0M |
| Q1 2024 | $47.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| RYBREVANT | AMIVANTAMAB-VMJW | 350MG/7ML (50MG/ML) | Injection |
1 product